Understand the source comparison
IGF-1 LR3 vs Native IGF-1: Structural and Functional Comparison
Understanding the IGF-1 LR3 history requires clarity on how the modified peptide differs functionally from the endogenous molecule. The table below summarizes the key structural and pharmacokinetic distinctions that made IGF-1 LR3 valuable as a research tool.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding the IGF-1 LR3 history requires clarity on how the modified peptide differs functionally from the endogenous molecule. The table below summarizes the key structural and pharmacokinetic distinctions that made IGF-1 LR3 valuable as a research tool.
- Amino Acid Length
- 70 amino acids
- 83 amino acids (13 AA N-terminal extension)
- Extended structure reduces proteolytic degradation
- Position 3 Residue
- Arginine (R)
- Glutamic acid (E). R3 substitution
- Dramatically lowers IGFBP binding affinity
- IGFBP Binding
- >99% bound in serum
- <10% bound in serum
- LR3 remains biologically active without sequestration
- Circulating Half-Life
- 10–12 minutes
- 20–30 hours
- Enables sustained receptor activation in experiments
- Receptor Affinity
- High affinity for IGF-1R
- Similar affinity for IGF-1R
- Both activate same signaling pathways
- Primary Research Use
- Difficult to study in isolation due to rapid clearance
- Preferred for studying direct IGF-1 receptor effects
- LR3 eliminates confounding variables from binding proteins
- This comparison reveals why the IGF-1 LR3 history is fundamentally a history of solving a methodological problem. How to study a growth factor whose biological activity is almost entirely regulated by binding proteins rather than receptor availability. The modifications preserved receptor activation while removing the biological brakes.